Updated Incyte combo data for epacadostat/Keytruda look promising
Incyte this morning teed up a fresh look at data from its early-stage study of its closely watched IDO1 drug epacadostat combined with Merck’s PD …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
